54 results about "Uterine leiomyoma" patented technology

The present invention relates, inter alia, to compounds having the general formula:

in which: R¹ is a member selected from the group consisting of —OCH₃, —SCH₃, —N(CH₃)₂, —NHCH₃, —NC₄H₈, —NC₅H₁₀, —NC₄H₈O, —CHO, —CH(OH)CH₃, —C(O)CH₃, —O(CH₂)₂N(CH₃)₂, and —O(CH₂)₂NC₅H₁₀; R² is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., acetoxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, —SCN, S-acyl and —OC(O)R⁶, wherein R⁶ is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxy ester (e.g., —CH₂OCH₃) and alkoxy (—OCH₃); R³ is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R⁴ is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR⁵, wherein R⁵ is a member selected from the group consisting of hydrogen and alkyl.

In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.

Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.

A method for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery, and occluding the flow of blood through the least one uterine artery. The blood can be occluded by compression. The artery can be compressed by ligating the cardinal ligament. In addition, at least one uterosacral ligament can be ligated. In addition, the artery can be compressed by, clipping, stapling or clamping the cardinal ligament. The blood can also be occluded by coagulating the at least one artery. Coagulation can be done with a laser or a cauterizing device. A system for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery using a surgical suture passing device to extend a ligature around the ligament, and affixing a ligature around the cardinal ligament to occlude the flow of blood through at least one uterine artery. Also, a system for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery, providing an absorbable clip and/or staple, and affixing the clip and/or staple around the ligament to occlude the flow of blood through the at least one uterine artery.

Methods for treating hormone associated conditions, such as endometriosis, uterine leiomata, ovarian cancer, breast cancer, or vaginal bleeding, using LHRH antagonists and selective estrogen receptor modulators are disclosed. The methods include administering to a subject a combination of an LHRH antagonist and a selective estrogen receptor modulator. Pharmaceutical compositions and kits for use in the methods of the invention are also provided.

The invention provides a medicine for treating tumor and its preparation process, wherein the medicine is prepared from Baoniangsong, cyperus tuber, Chinese dates and fresh ginger through watering and boiling, merging the two filtrates, concentrating, alcohol deposition, cooling down to normal temperature, and seasoning the plaster form article. The medicine can be prepared into electuary, tablet or capsule.

Disclosed is a proprietary Chinese traditional medicine for treating hysteromyoma, process for preparation and quality controlling method, which is prepared from root of red rooted saliva, notoginseng, burred tuber, zedoary, peach kernels, Chinese angelica root, turtle shell, seaweed, eucommia bark, white atractylodes rhizome, barbat skullcap and cassia twig.

The invention belongs to the field of traditional Chinese medicines and discloses a traditional Chinese medicinal composition for treating uterine leiomyoma. The traditional Chinese medicinal composition mainly comprises the following traditional Chinese medicinal components in parts by weight: 10g of rhizoma sparganii, 10g of curcuma zedoary, 10g of root-bark of tree peony, 10g of cassia twig, 10g of peach kernel, 10g of safflower, 15g of rhizoma atractylodis, 15g of nutgrass galingale rhizome, 15g of prepared rhizome of rehmannia, 10-12g of fructus aurantii, 10-12g of red paeony root, 10-12g of eucommia bark and 10-12g of himalayan teasel root. The traditional Chinese medicinal composition has the functions of smoothening qi and activating blood and removing blood stasis and dispersing phlegm, is used for treating uterine fibroid and is low in toxic or side effect and definite in curative effect.

The invention discloses a pharmaceutical composition for treating leiomyoma of uterus and an application thereof and relates to the technical field of traditional Chinese medicines. The pharmaceutical composition comprises the following traditional Chinese medicinal materials in parts by weight: 35-42 parts of curcuma zedoary, 20-26 parts of leonurus, 18-25 parts of rhizoma sparganii, 18-25 parts of largehead atractylodes rhizome, 16-20 parts of Chinese angelica, 16-20 parts of root of bidentate achyranthes, 7-10 parts of liquorice and 5-8 parts of peach seed. The pharmaceutical composition disclosed by the invention can obviously improve symptom of myoma of uterus and inhibit growth of the myoma or eliminate the myoma, and can show the superiority of non-surgical treatment.

The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids.

The invention discloses a medicine for curing hysteromyoma. It uses alga, burred tuber, duchesnea, Chinese sage, liquorice, barbat skullcap, bistort, co donopsis pilosula root as materials. Through extraction, condensing, drying and crash the materials can be produced into extractive powder, then adds in accessories and produces the capsule. The medicine in the invention has functions of pathogen dispersing, stimulating circulation to end stasis, supporting the healthy energy. It can be applied to hysteromyoma, the symptom is the menstrual period is prolongs, and the quantity is overmuch, and so on. The medicine has an excellent effect and it has no toxin and side effects.

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The present invention discloses a kind of hysteromyoma treating suppository and its preparation process. The hysteromyoma treating suppository is prepared with danozol 10-20 wt%, stearic acid 10-20 wt% and semi-synthetic fatty acid ester 60-80 wt%. The preparation process includes the following steps: heating stearic acid and semi-synthetic fatty acid ester in water bath at 60-90 deg.c; adding danozol after cooling to 40-50 deg.c; preparing in hot smelting process and sealing and packing. The present invention has the beneficial effects of: raised curative effect, reduced toxic side effect on liver of the medicine, less stimulation on stomach, etc.

The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.

The present invention relates to a method of diagnosing and treating endometrial cavity-distorting leiomyoma using microRNA, and particularly, a composition and a kit for diagnosing uterine leiomyoma, the composition and the kit including an agent capable of detecting a microRNA expression level in a biological sample; a method of diagnosing uterine leiomyoma of a subject, the method including measuring a microRNA expression level in a biological sample from the subject, and diagnosing that the subject has uterine leiomyoma having endometrial cavity distortion or uterine leiomyoma having a likelihood of developing endometrial cavity distortion, when the microRNA expression level is downregulated; and a method of treating uterine leiomyoma, the method including measuring a microRNA expression level in a biological sample from a subject, and performing uterine leiomyoma treatment when the microRNA expression level is downregulated.